keyword
MENU ▼
Read by QxMD icon Read
search

New drugs for children and adolescents

keyword
https://www.readbyqxmd.com/read/27899001/drug-interventions-for-the-treatment-of-obesity-in-children-and-adolescents
#1
REVIEW
Emma Mead, Greg Atkinson, Bernd Richter, Maria-Inti Metzendorf, Louise Baur, Nicholas Finer, Eva Corpeleijn, Claire O'Malley, Louisa J Ells
BACKGROUND: Child and adolescent obesity has increased globally, and can be associated with significant short- and long-term health consequences. OBJECTIVES: To assess the efficacy of drug interventions for the treatment of obesity in children and adolescents. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, PubMed (subsets not available on Ovid), LILACS as well as the trial registers ICTRP (WHO) and ClinicalTrials.gov. Searches were undertaken from inception to March 2016...
November 29, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27884679/risk-stratified-staging-in-paediatric-hepatoblastoma-a-unified-analysis-from-the-children-s-hepatic-tumors-international-collaboration
#2
Rebecka L Meyers, Rudolf Maibach, Eiso Hiyama, Beate Häberle, Mark Krailo, Arun Rangaswami, Daniel C Aronson, Marcio H Malogolowkin, Giorgio Perilongo, Dietrich von Schweinitz, Marc Ansari, Dolores Lopez-Terrada, Yukichi Tanaka, Rita Alaggio, Ivo Leuschner, Tomoro Hishiki, Irene Schmid, Kenichiro Watanabe, Kenichi Yoshimura, Yurong Feng, Eugenia Rinaldi, Davide Saraceno, Marisa Derosa, Piotr Czauderna
BACKGROUND: Comparative assessment of treatment results in paediatric hepatoblastoma trials has been hampered by small patient numbers and the use of multiple disparate staging systems by the four major trial groups. To address this challenge, we formed a global coalition, the Children's Hepatic tumors International Collaboration (CHIC), with the aim of creating a common approach to staging and risk stratification in this rare cancer. METHODS: The CHIC steering committee-consisting of leadership from the four major cooperative trial groups (the International Childhood Liver Tumours Strategy Group, Children's Oncology Group, the German Society for Paediatric Oncology and Haematology, and the Japanese Study Group for Paediatric Liver Tumours)-created a shared international database that includes comprehensive data from 1605 children treated in eight multicentre hepatoblastoma trials over 25 years...
November 21, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27854508/new-repurposed-drugs-for-pediatric-multidrug-resistant-tuberculosis-practice-based-recommendations
#3
Elizabeth P Harausz, Anthony J Garcia-Prats, James A Seddon, H Simon Schaaf, Anneke C Hesseling, Jay Achar, Jonathan Bernheimer, Andrea Cruz, Lia D'Ambrosio, Anne Detjen, Stephen M Graham, Jennifer Hughes, Sylvie Jonckheere, Ben J Marais, Giovanni Battista Migliori, Lindsay McKenna, Alena Skrahina, Marina Tadolini, Peyton Wilson, Jennifer Furin
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents...
November 17, 2016: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/27807915/barriers-to-participation-in-industry-sponsored-clinical-trials-in-pediatric-type-2-diabetes
#4
Ryan Farrell, Kathleen Bethin, Georgeanna Klingensmith, William V Tamborlane, Rose Gubitosi-Klug
BACKGROUND: The rapid emergence of type 2 diabetes (T2D) in the pediatric population has left pediatric endocrinologists with limited artillery in terms of management. While multiple medications are available for adults, Food and Drug Administration (FDA)-approved medications in children are limited to only metformin and insulin. Additional treatment options require randomized controlled trials, yet heretofore several barriers at the participant and institutional level have impeded these studies from proceeding in children and adolescents...
November 3, 2016: Pediatric Diabetes
https://www.readbyqxmd.com/read/27779782/use-of-tumor-necrosis-factor-alpha-inhibitors-in-children-and-young-adults-with-juvenile-idiopathic-arthritis-or-rheumatoid-arthritis
#5
Wan-Ju Lee, Leslie Briars, Todd A Lee, Gregory S Calip, Katie J Suda, Glen T Schumock
OBJECTIVE: To characterize the use of tumor necrosis factor-alpha inhibitors (TNFI) in children with juvenile idiopathic arthritis (JIA) and young adults with rheumatoid arthritis (RA). METHODS: Patients with incident JIA or RA were identified using the Truven Health MarketScan Commercial Claims and Encounters database from 2009 to 2013. The incident diagnosis was defined as no prior claims with a JIA/RA code and no JIA/RA medications recorded during the previous 6 months...
October 25, 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27647230/response-to-pazopanib-in-two-pediatric-patients-with-pretreated-relapsing-synovial-sarcoma
#6
Michela Casanova, Eleonora Basso, Chiara Magni, Luca Bergamaschi, Stefano Chiaravalli, Roberto Carta, Elisa Tirtei, Maura Massimino, Franca Fagioli, Andrea Ferrari
Pazopanib is an oral multikinase inhibitor that has proved effective in adults treated for relapsing soft tissue sarcoma and synovial sarcoma in particular. Two cases are reported here of pediatric patients with pretreated relapsing synovial sarcoma whose tumors showed a prolonged response to pazopanib given on compassionate grounds. These results suggest that new agents found effective in adult patients might achieve similar results in adolescents with the same disease. Facilitating the availability of new drugs for children and adolescents is a major challenge for pediatric oncologists...
August 25, 2016: Tumori
https://www.readbyqxmd.com/read/27628527/predictors-of-non-drug-psychiatric-psychotherapeutic-treatment-in-children-and-adolescents-with-mental-or-behavioural-disorders
#7
Sascha Abbas, Peter Ihle, Jürgen-Bernhard Adler, Susanne Engel, Christian Günster, Martin Holtmann, Axel Kortevoss, Roland Linder, Werner Maier, Gerd Lehmkuhl, Ingrid Schubert
Children and adolescents with mental health problems need effective and safe therapies to support their emotional and social development and to avoid functional impairment and progress of social deficits. Though psychotropic drugs seem to be the preferential treatment, psychotherapy and psychosocial interventions are essential in mental health care. For Germany, current data on the utilization of psychotherapy and psychosocial interventions in children with mental health problems is lacking. To analyse why certain children and adolescents with mental or behavioural disorders do and others do not receive non-drug treatment, we assessed predictors associated with specific non-drug psychiatric/psychotherapeutic treatment including psychosocial interventions, psychotherapy and other non-drug treatments...
September 14, 2016: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/27582894/children-with-multiple-sclerosis-should-not-become-therapeutic-hostages
#8
REVIEW
Klaus Rose, Thomas Müller
BACKGROUND: Both the United States (US) Food and Drug Administration (FDA) and the European Union (EU) European Medicines Agency (EMA) order pediatric clinical trials as a condition for approval of new compounds. We evaluate clinical value and likelihood of sufficient recruitment for pediatric multiple sclerosis (pMS) studies and discuss US and EU pediatric legislation with pMS as a paradigm. METHODS: We analyzed pMS clinical trials requested by the FDA and the EMA and industry-sponsored pMS studies registered on www...
September 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27573084/contraception-for-hiv-infected-adolescents
#9
Athena P Kourtis, Ayesha Mirza
Access to high-quality reproductive health care is important for adolescents and young adults with HIV infection to prevent unintended pregnancies, sexually transmitted infections, and secondary transmission of HIV to partners and children. As perinatally HIV-infected children mature into adolescence and adulthood and new HIV infections among adolescents and young adults continue to occur in the United States, medical providers taking care of such individuals often face issues related to sexual and reproductive health...
September 2016: Pediatrics
https://www.readbyqxmd.com/read/27572854/pediatric-multiple-sclerosis-escalation-and-emerging-treatments
#10
Tanuja Chitnis, Angelo Ghezzi, Barbara Bajer-Kornek, Alexey Boyko, Gavin Giovannoni, Daniela Pohl
Over the last 20 years, there have been significant advances in multiple sclerosis (MS) therapeutics, with regulatory approval for 13 therapies in adults by the European Medicines Agency (EMA) and Food and Drug Administration. However, there is only limited approval for interferon-β and glatiramer acetate use in children 12 years and older by the EMA. Availability of disease-modifying therapies to children and adolescents with MS is variable by region, and is extremely limited in some regions of the world...
August 30, 2016: Neurology
https://www.readbyqxmd.com/read/27555642/inflammatory-bowel-disease-incidence-is-on-the-continuous-rise-among-all-pediatric-patients-except-for-the-very-young-a-nationwide-registry-based-study-on-28-year-follow-up
#11
Lauri J Virta, Maiju M Saarinen, Kaija-Leena Kolho
BACKGROUND AND AIMS: The burden of inflammatory bowel disease (IBD) in health care is high. We conducted research on the temporal changes in the incidence of pediatric IBD (PIBD) using nationwide registry-based data in Finland. METHODS: All PIBD cases diagnosed at less than 20 years of age during 1987-2014 (in total, 5,415 patients) were retrieved from a database documenting reimbursements for drug costs. Incidence rates were calculated by dividing the number of annual new PIBD cases by the size of the pediatric population at risk during each calendar year...
August 23, 2016: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/27521067/2016-american-thyroid-association-guidelines-for-diagnosis-and-management-of-hyperthyroidism-and-other-causes-of-thyrotoxicosis
#12
Douglas S Ross, Henry B Burch, David S Cooper, M Carol Greenlee, Peter Laurberg, Ana Luiza Maia, Scott A Rivkees, Mary Samuels, Julie Ann Sosa, Marius N Stan, Martin A Walter
BACKGROUND: Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions and patient preference. This document describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist and subspecialty physicians and others providing care for patients with this condition. METHODS: The American Thyroid Association (ATA) previously cosponsored guidelines for the management of thyrotoxicosis that were published in 2011...
October 2016: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/27395403/aripiprazole-and-acute-extrapyramidal-symptoms-in-children-and-adolescents-a-meta-analysis
#13
REVIEW
Chiara Bernagie, Marina Danckaerts, Martien Wampers, Marc De Hert
BACKGROUND: Both the US FDA and the European Medicines Agency (EMA) have approved aripiprazole for use in adolescents for specific indications. Given the assumed favorable side-effect profile of aripiprazole, its use in children and adolescents has increased for both official and off-label indications (anxiety disorders, eating disorders, personality disorders). However, several cases of children and adolescents with new-onset extrapyramidal symptoms (EPS) after commencing treatment with aripiprazole have been reported, and a more systematic appraisal of this possible risk is lacking...
September 2016: CNS Drugs
https://www.readbyqxmd.com/read/27374377/psychopharmacological-prescriptions-in-children-and-adolescents-in-germany
#14
Sascha Abbas, Peter Ihle, Jürgen-Bernhard Adler, Susanne Engel, Christian Günster, Roland Linder, Gerd Lehmkuhl, Ingrid Schübert
BACKGROUND: In view of the well-known increase in prescriptions of stimulants for children and adolescents over the last 20 years, it is important to study trends in the prevalence and incidence of the use of other psychotropic drugs by this age group as well, to enable an early response to potential problems in the current care situation. METHODS: We used nationwide data from German statutory health insurance funds (Allgemeine Ortskrankenkasse [AOK], all insurees; Techniker Kranken - kasse [TK], a 50% randomized sample) concerning all insurees aged 0-17 years (5...
June 6, 2016: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/27358151/efficacy-and-safety-of-omalizumab-in-paediatric-age-an-update-of-literature-data
#15
N Matin, O Tabatabaie, R Falsaperla, P Pavone, A Serra, S Cocuzza, P Di Mauro, L Licciardello, R Lubrano, G Vitaliti
Immunoglobulin E (IgE) was discovered in 1966 and was found responsible for immune defense against helminths, type I hypersensitivity and allergic diseases. IgE mediates allergic responses by binding to Fc receptors (the high affinity Fc-epsilon receptor I and the low affinity Fc-epsilon receptor II or CD23) expressed on tissue mast cells and blood basophils. This binding leads to degranulation and release of pro-inflammatory mediators. Considering the pivotal role of IgE in allergic diseases, antibodies against IgE potentiate an array of new therapeutic strategies and in this regard omalizumab (rhuMAb-E25, Xolair) has been developed as a monoclonal biologic drug to block serum IgEs...
April 2016: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/27344135/aripiprazole-for-autism-spectrum-disorders-asd
#16
REVIEW
Lauren E Hirsch, Tamara Pringsheim
BACKGROUND: Autism spectrum disorders (ASD) include autistic disorder, Asperger's disorder and pervasive developmental disorder - not otherwise specified (PDD-NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third-generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011)...
2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27300094/-trends-in-abuse-of-biogenic-drugs-in-parts-of-germany-2007-2013
#17
J Pietsch, K Scheffel, D Acquarone, I Koch, M Deters, M Hermanns-Clausen
Aim of the study: Based on an abundance of information on the internet, psychotropic plants and mushrooms are of increasing relevance as legal and cheap alternatives to other illicit drugs. Due to the lack of a German database, the abuse of selected biogenic drugs using reported exposures to 3 German Poison Information Centres (PICs) was examined. Methods: Information on abuse of biogenic drugs was collected from the German PICs in Berlin, Erfurt and Fribourg (2007-2013). Results: 602 drug abuses were reported to the selected PICs...
June 14, 2016: Das Gesundheitswesen
https://www.readbyqxmd.com/read/27294308/universal-antiretroviral-treatment-eligibility-for-children-and-adolescents-living-with-hiv-a-new-era
#18
Eric J Dziuban, Emilia D Rivadeneira
Antiretroviral treatment coverage for children living with HIV is low, and new efforts are underway to expand eligibility so that all children and adolescents qualify for treatment regardless of immune suppression or clinical stage. While recent trials provide direct evidence of the benefit of this approach in adults, no such studies have been performed in children. This paper examines the available body of evidence regarding universal HIV treatment for children and adolescents. The benefits and challenges for individual patient health, as well as programmatic-level outcomes, are assessed...
June 10, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27258969/implementation-of-mechanism-of-action-biology-driven-early-drug-development-for-children-with-cancer
#19
Andrew D J Pearson, Ralf Herold, Raphaël Rousseau, Chris Copland, Brigid Bradley-Garelik, Debbie Binner, Renaud Capdeville, Hubert Caron, Jacqueline Carleer, Louis Chesler, Birgit Geoerger, Pamela Kearns, Lynley V Marshall, Stefan M Pfister, Gudrun Schleiermacher, Jeffrey Skolnik, Cesare Spadoni, Jaroslav Sterba, Hendrick van den Berg, Martina Uttenreuther-Fischer, Olaf Witt, Koen Norga, Gilles Vassal
An urgent need remains for new paediatric oncology drugs to cure children who die from cancer and to reduce drug-related sequelae in survivors. In 2007, the European Paediatric Regulation came into law requiring industry to create paediatric drug (all types of medicinal products) development programmes alongside those for adults. Unfortunately, paediatric drug development is still largely centred on adult conditions and not a mechanism of action (MoA)-based model, even though this would be more logical for childhood tumours as these have much fewer non-synonymous coding mutations than adult malignancies...
July 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27249542/advancing-pharmacologic-treatment-options-for-pharmacologic-treatment-options-for-children-with-epilepsy
#20
Stéphane Auvin
INTRODUCTION: The pharmacological management of epilepsy is continually modified by the increase in our knowledge about the efficacy and the safety on antiepileptic drugs. AREAS COVERED: This review covers the published data (2010-2015) on the pharmacological management of epilepsy in children and adolescent. We review the data from the most recent randomized controlled and open-label trials. EXPERT OPINION: Even if there is an increasing number of antiepileptic drugs approved for focal seizure in children and adolescent with epilepsy, each new approval would be considered as a significant addition to the current therapeutic options...
August 2016: Expert Opinion on Pharmacotherapy
keyword
keyword
39032
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"